Damon(SH:688360)2024-04-29 09:04Financial Performance - The company's operating revenue for Q1 2024 was ¥279,559,928.41, representing a decrease of 5.78% compared to the same period last year[5]. - Net profit attributable to shareholders was ¥21,214,731.43, showing a slight decline of 0.55% year-over-year[5]. - The net profit after deducting non-recurring gains and losses increased by 9.65% to ¥18,461,626.37[5]. - Total revenue for Q1 2024 was CNY 279,559,928.41, a decrease of 5.4% compared to CNY 296,708,959.69 in Q1 2023[19]. - Net profit for Q1 2024 was CNY 20,349,235.39, a slight decrease from CNY 21,331,304.13 in Q1 2023, representing a decline of 4.6%[20]. - The company's total assets increased to CNY 2,598,966,135.10 in Q1 2024, up from CNY 2,537,552,626.50 in Q1 2023, marking a growth of 2.4%[18]. - The company's long-term equity investments increased to ¥77,874,755.24 from ¥52,517,058.09, marking a growth of approximately 48.2%[15]. Cash Flow and Investments - The net cash flow from operating activities was negative at -¥56,391,635.72, primarily due to timing differences in cash collections from sales[9]. - The company's cash flow from operating activities for Q1 2024 showed a positive trend, although specific figures were not disclosed in the provided content[22]. - In Q1 2024, the cash inflow from sales and services was approximately ¥225.93 million, an increase of 6.9% compared to ¥213.08 million in Q1 2023[23]. - Cash outflow for purchasing goods and services was ¥178.04 million, up from ¥148.68 million in Q1 2023, reflecting a 19.7% increase[23]. - Investment activities generated a net cash outflow of ¥42.04 million, compared to a net outflow of ¥23.39 million in Q1 2023, indicating increased investment expenditures[24]. - The cash inflow from financing activities was ¥75.12 million, significantly higher than ¥11.05 million in Q1 2023, showing improved financing efforts[24]. - The ending cash and cash equivalents balance was ¥337.62 million, up from ¥219.32 million at the end of Q1 2023, representing a 53.9% increase[24]. - The company received ¥75.11 million in borrowings, a substantial increase from ¥9.46 million in Q1 2023, indicating stronger borrowing activity[24]. Research and Development - The total R&D investment amounted to ¥20,873,132.09, which is an increase of 28.33% year-over-year, accounting for 7.47% of operating revenue, up by 1.99 percentage points[6]. - Research and development expenses increased to CNY 20,873,132.09 in Q1 2024, up from CNY 16,265,065.15 in Q1 2023, reflecting a growth of 28.5%[20]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 7,083[11]. - The company reported a total of 48,024,174 shares held by Huzhou Derma Investment Consulting Co., Ltd., representing the largest shareholder with a 35.69% stake[12]. - The top ten shareholders collectively hold significant stakes, with the largest shareholder alone holding 35.69% of the total shares[12]. - The company has not reported any changes in the participation of major shareholders in margin trading or securities lending activities[13]. - The company is under the control of Zhuo Xu, who also holds a 1.92% stake in Huzhou Ligu Management Consulting Co., Ltd.[13]. Asset and Liability Overview - Total assets at the end of the reporting period were ¥2,598,966,135.10, reflecting a growth of 2.42% from the end of the previous year[6]. - Total liabilities rose to CNY 1,243,301,503.42 in Q1 2024, compared to CNY 1,203,480,323.63 in Q1 2023, indicating an increase of 3.3%[18]. - Total current assets reached ¥1,715,976,180.25, compared to ¥1,691,057,395.31, showing a slight increase of about 1.5%[16]. Other Notable Points - The company has not disclosed any new product developments or market expansion strategies in this report[1]. - The company has not disclosed any significant new strategies or product developments during the reporting period[14]. - The weighted average return on net assets decreased by 0.53 percentage points to 1.59%[5]. - The company reported non-recurring gains of ¥2,753,105.06 for the period, after accounting for tax effects[8]. - The company experienced a credit impairment loss of CNY -4,566,190.42 in Q1 2024, contrasting with a gain of CNY 2,528,359.81 in Q1 2023[20]. - The company reported a basic earnings per share of CNY 0.16 for Q1 2024, down from CNY 0.18 in Q1 2023[21]. - The total equity attributable to shareholders increased to CNY 1,347,983,496.76 in Q1 2024, compared to CNY 1,325,525,671.91 in Q1 2023, showing a growth of 1.7%[18].